Les meilleurs doctors en Israël pour votre Chimiothérapie - TOP 32 des médecins

Le Dr Pelles Sharon est spécialisé dans les techniques de chimiothérapie avancées, y compris la chimiothérapie intrapéritonéale hyperthermique (HIPEC) au Centre médical Sourasky.

• Expert en immunothérapie et en thérapie ciblée pour divers cancers
• A mené des recherches cliniques sur les attitudes des patients envers les essais
• Effectue des procédures complexes comme la chirurgie de Whipple et les résections hépatiques
• Propose de multiples approches de chimiothérapie adaptées au type de cancer

Expert de premier plan en sarcomes et en oncologie orthopédique, bénéficiant d'une vaste expérience clinique et de recherche au Centre médical Sourasky.

• Chef de l'Unité d'oncologie des tissus mous et osseuse depuis 2000
• Formation de boursier (fellowship) complétée à l'Institut Gustave Roussy, Paris
• Membre du corps professoral du groupe Sarcome de l'ESMO
• Travaux pionniers en recherche sur l'immunologie tumorale
• Ancien président de la Société israélienne d'oncologie et de radiothérapie

Le Dr Sarid est un oncologue chevronné au Centre médical Sourasky, avec plus de 15 ans d'expérience, spécialisé en chimiothérapie et en thérapie biologique du cancer.

• Oncologue sénior au Centre médical Sourasky depuis 2009
• Investigateur principal d'essais cliniques en thérapies anticancéreuses
• Auteur de plus de 30 articles sur le traitement du cancer
• Membre de la Société européenne d'oncologie médicale et de la Société américaine d'oncologie clinique
• Formation à l'Université d'Oxford avec une spécialité en urologie oncologique

Spécialiste en Gynécologie Oncologique et Radiothérapie – Tamar Sapra apporte son expertise ciblée au traitement par chimiothérapie au Centre Médical Sourasky (Ichilov).

• Se spécialise dans les cas d'oncologie gynécologique
• Combine la chimiothérapie avec la radiothérapie pour des soins complets
• Travaille dans l'un des principaux centres médicaux d'Israël

Dr. Hana Golan, MD, heads the Pediatric Hemato-Oncology and Bone Marrow Transplantation (BMT) Division at Sheba Medical Center. She specializes in childhood cancers, with a focus on neuroblastoma and other high-risk solid tumors.

She leads one of the region’s most advanced pediatric oncology programs. She manages complex, high-risk cases and practices at a hospital ranked in the global top 10.

She is the principal investigator of the High-Risk Neuroblastoma ESIOP protocol. She serves as an investigator in international Phase I/II trials and as the national coordinator of multicenter oncology protocols. She led the development of computerized chemotherapy protocols and patient databases to improve safety.

She earned her MD from the Technion. She completed residencies in pediatrics and pediatric hemato-oncology at Sheba. She conducted advanced research in transplantation immunology at the Weizmann Institute. She is board-certified in Pediatrics and Pediatric Hematology-Oncology. She is a Senior Lecturer at the Sackler Faculty of Medicine, Tel Aviv University. Her research focuses on cancer stem cells, targeted therapies, treatment-resistant malignancies, and cannabinoid-related oncology.

Prof. Amit Tirosh is a senior endocrinologist and Head of the Neuroendocrine Tumors Service at Sheba Medical Center. He specializes in neuroendocrine tumors (NETs).

His work centers on hereditary NET syndromes. He is affiliated with the NIH in MEN1 research. He serves on an international VHL expert panel and helped write VHL management guidelines. He is the primary contact at Sheba’s multidisciplinary VHL clinic.

He leads the Endocrine Oncology Bioinformatics Lab. He collaborates with international teams, including the Weizmann Institute. He provides advanced NET care, including PRRT.

He earned his MD from the Hebrew University–Hadassah. He completed a residency at Assaf HaRofeh, an endocrinology fellowship at Rabin, and training at the NIH. He is board-certified in Endocrinology. He is a member of the Israeli Society of Endocrinology, the Endocrine Society, and the European Neuroendocrine Tumor Society. He has authored over 40 peer-reviewed papers, including in JAMA, Gastroenterology, and Radiology.

Dr. Yuri Goldes is a general surgeon with more than 20 years of clinical experience. He specializes in upper gastrointestinal and oncologic surgery. He is Deputy Director of the Department of General Surgery and Transplantation at Sheba Medical Center in Tel Aviv. He also leads the Upper GI Surgery Unit. He was named to Forbes Israel’s Best Doctors in 2025. He is ranked among Israel’s Best Gastrointestinal Surgeons by Forbes. In 2019, he received the Israeli Ministry of Health “Best Doctor of the Year” award.

He is an expert in advanced minimally invasive and robotic surgery. He treats diaphragmatic hernia, achalasia, GERD, and gallbladder disease. He also performs oncologic surgery for pancreatic, gastric, and esophageal cancers. He uses laparoscopic and robotic techniques.

He pioneered some of Israel’s first robotic oncologic resections of the stomach and pancreas. He is among a small group worldwide who perform minimally invasive Whipple procedures (pancreaticoduodenectomy) using advanced laparoscopy. He applies methods that improve outcomes and speed recovery. He provides personalized care.

Le Dr Ari Raphael dirige des recherches révolutionnaires sur le cancer du poumon et du sein au centre médical Sourasky, en se concentrant sur la médecine génomique et l'immunothérapie.

• Investigateur principal pour les essais cliniques sur le pembrolizumab et l'immunothérapie néoadjuvante
• Expert en profilage génomique complet et biopsies liquides
• Modérateur du Conseil Moléculaire des Tumeurs pour la Société Israélienne du Cancer du Poumon
• Enseignant exceptionnel à la faculté de médecine de l'université de Tel-Aviv

Chef de la Division d'Oncologie Médicale au Centre Médical Sourasky – le Dr Wolf est spécialisé dans les traitements de chimiothérapie avancée.

• Vaste expérience en oncologie et en médecine interne
• Diplôme de l'Université Ben Gourion du Néguev
• Ancien service au sein d'unités médicales de l'armée
• Parle couramment anglais pour les patients internationaux

Le Dr Dvora Blumental a dirigé les services de neuro-oncologie au sein d'institutions de premier plan, telles que le Huntsman Cancer Institute et le Sourasky Medical Center.

• Spécialisée en neuro-oncologie avec plus de 25 ans d'expérience
• Formation acquise au Memorial Sloan-Kettering Cancer Center
• Directrice du Service de Neuro-oncologie à l'Institut d'Oncologie
• Experte dans le traitement des cancers du cerveau et du système nerveux

Le Dr Michael Shapira est spécialisé en Transplantation de Moelle Osseuse et possède plus de 20 ans d'expérience depuis l'obtention de son diplôme à la Faculté de médecine de l'Université Hébraïque.

• Médecin senior dans le département de Transplantation de Moelle Osseuse au Hadassah Medical Center
• Formation en médecine interne effectuée au Hadassah Medical Center
• Parle couramment l'anglais et l'hébreu pour une communication aisée avec les patients

Le Dr Dror Levin est spécialisé en hémato-oncologie pédiatrique, se concentrant sur le cancer des os (sarcome) chez les enfants. Il dirige le service d'hémato-oncologie pédiatrique au Centre médical Sourasky à Tel Aviv.

• Pédiatre senior à l'Hôpital pour enfants « Dana »
• Spécialisé en hématologie et oncologie pédiatriques au Centre médical pour enfants Schneider
• Formation en oncologie osseuse et des tissus mous à l'Institut orthopédique Rizzoli en Italie
• Membre de l'association israélienne d'hémato-oncologie pédiatrique (ISPHO)

Le Dr Fredi Aviv apporte 31 ans d'expérience spécialisée en oncohématologie, acquise au Centre médical Sourasky.

• Spécialisé en chimiothérapie pour les cancers hématologiques (cancers du sang)
• Exerce dans l'un des principaux centres médicaux d'Israël
• Certifié par le Conseil (Board-certified) en oncohématologie

Directeur de l'hospitalisation en oncologie au Centre médical de Tel Aviv, le Dr Stepfansky dirige une équipe d'oncologie dévouée à Ichilov.

• Plus de 15 ans d'expérience en oncologie
• Spécialisation en médecine interne avant de se concentrer sur l'oncologie
• Chercheur principal dans les essais cliniques de phase I à III
• Formé au sein du programme d'oncologie prestigieux du Centre médical de Tel Aviv

Le Dr Sonnenblick est spécialisé dans les traitements du cancer du sein, notamment la chimiothérapie, la radiothérapie et les thérapies ciblées comme Keytruda. Il a présenté des travaux lors de plus de 30 réunions scientifiques nationales et internationales.

• Lauréat de plusieurs prix, dont le « ESMO Breast Cancer Translational Research Award »
• Membre de sociétés d'oncologie prestigieuses telles que l'ESMO et l'EACR
• A suivi une formation de perfectionnement (fellowship) en recherche sur le cancer du sein à l'Université Emory et à l'Institut Jules Bordet

Dr. Hila Magen, MD, leads the Multiple Myeloma and Amyloidosis Unit at Sheba Medical Center. She is a hemato-oncologist with over 35 years of experience. She is a leading Israeli expert in multiple myeloma and plasma cell disorders.

She runs a program that provides personalized care and early access to clinical trials. This includes CAR-T therapy for high-risk and relapsed or refractory myeloma and amyloidosis. Dr. Magen is a principal investigator in point-of-care CAR-T studies. She brings new immunotherapies into routine care.

Training: Fellowships in Multiple Myeloma (UAMS) and Lymphocytic Leukemia (MD Anderson). Academic: Instructor, Tel Aviv University. Research: Author of 100+ publications, contributor to landmark myeloma studies, and reviewer for international journals.

Dr. Iris Kventsel, MD, is a pediatric hemato-oncologist and bone marrow transplant (BMT) specialist at Sheba Medical Center. She is an attending physician in the Pediatric Hemato-Oncology and BMT Division at the Edmond and Lily Safra Children’s Hospital. Her clinical focus is pediatric sarcomas, including Ewing sarcoma, osteosarcoma, and rhabdomyosarcoma.

She provides multidisciplinary care, including transplant and cellular therapies. She also uses current chemotherapy protocols and targeted therapies for complex childhood cancers.

Her research focuses on genetic cancer predisposition, including Li-Fraumeni syndrome, and cancer susceptibility genes. She has published in pediatric oncology, stem cell biology, and surgical oncology (HIPEC). She is on the academic staff at Tel Aviv University. Education: MD, Technion; Pediatrics residency, Assaf HaRofeh; Pediatric Hemato-Oncology fellowship, Sheba.

Prof. Elad Jacoby, MD, heads the Pediatric Cell Therapy Center at Sheba Medical Center. He is the Medical Director of the Advanced Biotherapy Center. He is a pioneer of pediatric CAR T‑cell therapy in Israel. He led one of the first national leukemia programs. He has almost 20 years of clinical and research experience.

He specializes in CAR T‑cell therapy, bone marrow and stem cell transplantation, and high‑risk pediatric leukemias and lymphomas. He leads international clinical trials and has authored over 240 publications. His collaborations include Johns Hopkins Hospital and the U.S. National Cancer Institute. He is an Associate Professor at Tel Aviv University. He received his MD from Tel Aviv University, completed residency at Sheba Medical Center, and fellowships at Johns Hopkins and the National Cancer Institute. He is board‑certified in Pediatrics and in Pediatric Hematology and Oncology. He serves on the IBFM CAR T‑Cell Taskforce and the Sheba Institutional Review Board. He leads the integration of CAR T‑cell therapy with transplantation.

Dr. Eytan Aharon Ben‑Ami, MD, is a Senior Physician in the Sarcoma and Bone Oncology Service at Sheba Medical Center. He heads the Oncology Division and the Early-Phase Clinical Trials Unit. He founded the Sheba Clinical Research Organization. He is an academic affiliate at Tel Aviv University.

He specializes in sarcomas and primary bone tumors, including soft tissue sarcoma, liposarcoma, leiomyosarcoma, and osteosarcoma. He leads Phase I trials in targeted therapy and immunotherapy. He designs personalized treatment plans for rare cancers. He also develops patient-centered programs, including pilots in advanced immunotherapy delivery.

He completed a fellowship in Sarcoma and Bone Oncology at the Dana-Farber Cancer Institute/Harvard Cancer Center. He has authored more than 40 publications on early detection, molecular and viral mechanisms, and new cancer therapies.

Prof. Ben Boursi is a physician in the Gastrointestinal Cancer Department at Sheba Medical Center. He specializes in internal medicine, medical oncology, and cancer epidemiology. He is board certified in internal medicine and medical oncology. He earned a B.Med.Sc (summa cum laude) and an MD (magna cum laude) from Tel Aviv University.

He completed clinical and research fellowships in GI oncology and cancer epidemiology at the University of Pennsylvania. He also completed electives at MD Anderson and Mayo Clinic. He founded the ECOG-ACRIN Microbiome Working Group. His microbiome-oncology research has been published in leading journals, including Science, and highlighted by ASCO.

He developed predictive models for early diagnosis of colorectal and pancreatic cancers. These models are now in clinical evaluation. He holds an academic appointment at Tel Aviv University. He is also an Associate Scholar at the University of Pennsylvania.